Diabetes and Cardiovascular Disease: Evaluation, Prevention, & Management Nathan D Wong, Shaista Malik
INDEX
ABCDEFGHIJKLMNOPRSTUVW
Page numbers followed by f refer to figure and t refer to table.
A
Abdomen subcutaneous fat 34
Abdominal circumference 34
Acute coronary events, global registry of 97
Alanine aminotransferase 54
Alpha-glucosidase inhibitor 113
Ambulatory blood pressure monitoring 70
American Association of Clinical Endocrinologists 113
American College of
Cardiology 16, 20, 38, 50, 44
Sports Medicine 27
American Diabetes Association 2, 20, 37, 47, 68, 130
American Heart Association 5, 16, 50, 27, 44, 130
Amylin
agonists 121
analog 106
Anemia 83
Angiotensin
converting enzyme inhibition 66, 85, 101
receptor blockers 72, 85, 121
Ankle brachial index 20
Antihyperglycemic agents 111
Anti-oxidant deficiency 83
Apolipoprotein B 55
Asymmetric dimethyl arginine 83
Atherogenic dyslipidemia 45
Atherosclerosis, multi-ethnic study of 11
Atherosclerotic lesion 44
B
Bile acid sequestrant's 105, 106
Blood pressure 34, 61, 61, 65f, 80, 87
Body mass index 4, 27, 34, 112
Bromocriptine mesylate 118
C
Caffeine 34
Calcium channel blocker 72
Cardiovascular disease 1, 4, 5, 7, 10, 14, 18, 26, 29, 34, 45, 61, 79, 83, 97, 99, 129
atherosclerotic 47, 50, 96
development of 28, 79, 82
in diabetes 14
management of 86
novel markers of 21
Cardiovascular health study 49
Carotid intima media thickness 20, 56
Centers for Disease Control 27, 130
Cholesterol 34
ester 55
transfer protein 46, 55
Chronic kidney disease 79, 80, 81f, 82, 83, 86, 99
dyslipidemia of 84
prevalence of 86
Collaborative atorvastatin diabetes study 50
Computerized decision-support systems 135
Congestive heart failure 80, 119
Coronary artery
calcification 84, 101
calcium 18, 56
disease 3, 15, 49, 61, 98
risk development 16, 48
Coronary heart disease 7, 28, 34, 43, 88, 99
evaluation 51
status 34t
C-reactive protein 17
D
Density lipoprotein, low 130
Diabetes 32, 37, 61, 69
and cardiovascular disease, epidemiology of 1
and vascular disease, action in 73
control and complications trial 100, 130
development of 31
electronic management system 136
epidemiology 4
lifestyle management in 26
masked hypertension in 70
mellitus 15, 61–63, 79, 96, 97, 114
type 1 98
type 2 2
prevention program 32
Diabetic dyslipidemia 43
Diabetic retinopathy, identification of 2
Diastolic blood pressure 34, 61
Dipeptidyl peptidase-4 inhibitors 105, 106, 114
Dizziness 119
Dual-energy X-ray absorptiometry 120
Dyslipidemia 83
in diabetes, evaluation and treatment of 47
E
Electronic medical records 133
Endothelial dysfunction 45
End-stage renal disease 79
Erythrocyte sedimentation rate 17
Estimated glomerular filtration rate 74, 80
European Society of
Cardiology 68
Hypertension 68
Extra-cellular volume 80
F
Fasting glucose 34
Fatal atherosclerotic cardiovascular disease 96
Fatigue 119
Finnish Diabetes Prevention Study, 32
Food and drug administration 111
Framingham heart study 6, 7, 49
Free fatty acid 45, 55
G
Gastrointestinal tract 83
Glinides 105
Glomerular filtration rate 113
Glucagon-like peptide-1 105
analogs 106
receptor agonists 115
Glucose dependent insulinotropic polypeptide 104
Glycation end-products, advanced 99
Glycemia 89
Glycemic index 33, 35
Glycosylated hemoglobin 85
Guideline utilization 138
H
HDL cholesterol 34, 84
Headache 119
Health
care systems 132
information technology 129, 135
maintenance organizations 133, 134
plan employer data and information set scores 132, 133
Heart
attack trial 74
protection study 50
High blood pressure, evaluation and treatment of 29
High pro-atherogenic HDL-cholesterol 84
High triglycerides 84
High-density lipoprotein 4, 16, 34, 84
cholesterol 55, 98
levels 27
Homocysteine 83
Honolulu heart program 31
Hydrochlorothiazide 73
Hyperfiltration 80
Hyperglycemia 99
pathophysiology of 104
Hyperphosphatemia 83
Hypertension 8, 61, 63f, 69f, 70, 83
optimal treatment study 64
prevalence of 62
Hyperuricemia 83
Hypoglycemia 111, 122f
Hypothalamic-pituitary-adrenal axis 118
I
Impaired fasting glucose 2, 97
Indoxyl sulphate 83
Infarction, myocardial 2, 7, 43, 50
Inflammation and oxidative stress 83
Insulin 9, 105, 108
resistance 44
homeostasis model assessment of 9
International expert committee 2
Intra-abdominal fat 34
Ischemia, myocardial 11, 43
J
Joint National Committee on Prevention 29
K
Kidney disease improving global outcomes 80
L
LDL cholesterol 34, 84
Lipids 87
and lipoproteins 8
Lipoprotein lipase 45
Low-density lipoprotein 4, 16, 18, 34, 44, 84
cholesterol 50, 98
levels 27
secretion 5
M
Macroalbuminuria 86
Macrophage colony-stimulating factor 45
Magnetic perfusion imaging 20
Magnetic resonance imaging 117
Meglitinides 109
Metformin 106, 112
Microalbuminuria 86
Microsomal transfer protein 46
N
National Cholesterol Education Program 48
National Committee for quality assurance 132
National Diabetes Prevention Program 131
National Health and Nutrition Examination Survey 6, 27
National Institutes of Health 28
Nausea 119
New York Heart Association 118
Non-hemorrhagic stroke 80
Noninvasive imaging techniques 18
O
Obesity 7, 29, 32
Oral glucose tolerance test 2, 98
Orthostasis 119
P
Para-cresol sulfate 83
Parathormone 83
Physician quality reporting system 142
Prediabetes 97
and cardiovascular disease 4
R
Renin-angiotensin
aldosterone system 62, 72
system 86
S
San Antonio Heart Study 7
Single-nucleotide polymorphism 21
Somnolence 119
Stress myocardial perfusion imaging, role of 20
Sugar-sweetened beverages 36
Sulfonylureas 105, 109
Systematic coronary risk evaluation 16
Systems structure 132
Systolic hypertension, systolic 9, 63, 73
T
Thiazolidinediones 105–107, 116
Total cholesterol 16
Triglycerides 34, 45
U
United Kingdom prospective diabetes study 4, 16, 100, 130
Uremic toxins 83
Urinary albumin:creatinine ratio 80
V
Vascular calcification 83
Very low-density lipoprotein 45, 84, 99
Vitamin D
and calcium 35
deficiency 83, 90
Vomiting 119
W
Waist-hip ratios 8, 29
World Health Organization's 29
×
Chapter Notes

Save Clear